RVMD ▼ -0.6% - Revolution Medicines, Inc. $RVMD - zoldonrasib Receives orphan drug designation Revolution Medicines shares declined 0.6% despite the company's announcement that the FDA has granted orphan drug designation to zoldonrasib, its investigational therapeutic candidate. Orphan drug status typically accelerates development timelines and provides regulatory incentives, though the modest stock reaction suggests investors may have already anticipated this designation or are awaiting clinical efficacy data. 15-SEP-2026 02:52 PM ET